CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 885 enrolled
Drug / intervention
mRNA-1010 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04956575
NCT04956575Phase 2Completed
CompareCT.gov

A Phase 1/2, Randomized, Stratified, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults 18 Years and Older

ModernaTX, Inc.·interventional·Posted Jul 9, 2021·Updated Oct 27, 2023

In Brief

A Phase 2 clinical trial evaluating mRNA-1010, Placebo, and 1 other intervention for Seasonal Influenza. Completed, enrolled 885 participants across 21 sites.

Detailed Summary

The study comprises 3 parts: Phase 1/2, Phase 2 Northern Hemisphere (NH), and Phase 2 extension. The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1010 vaccine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Influenza
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJul 9, 2021
Enrollment StartJul 6, 2021
Primary CompletionSep 27, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.0 years ago

Interventions

mRNA-1010biological

Sterile liquid for injection

Placebobiological

0.9% sodium chloride solution for injection

Active Comparatorbiological

0.5 milliliter (mL) intramuscular (IM) injection